IV Infusion Therapy and Peptide Therapy

IV Infusion Therapy

IV Infusion Therapy

Glutathione Therapy

Glutathione is known as the master antioxidant, a naturally-occurring antioxidant produced by the human liver. It prevents damage due to free radicals, heavy metals, and other substances toxic to the body. Known as the body’s most important antioxidant, Glutathione can help fight off almost any disease – especially those that cause you to age faster than you should.
Glutathione donates electrons to quench free radicals, ultimately protecting cells from being destroyed. If glutathione is depleted in a cell, it will lead to cell death. Glutathione protects cells of many types, especially the skin, lens, retina, intestinal lining, and cornea. It is also a cofactor in many bodily processes and is the foundation for the main detoxification pathway in the liver, kidneys, lungs, intestinal lining, and other organs. Glutathione has been the subject of scientific research for many years. Studies have shown that levels of glutathione directly correspond to the health and function of cells.>
As your body ages, it produces less Glutathione each year. In the form of injections, Glutathione can slow down the aging process and makes sure that your body has what it needs to fight off free radicals.
Glutathione therapy is best for detoxing and cleansing vital organs, rejuvenating skin, hair and nails, and reversing the effects of aging.
Intravenous Glutathione treatments have been proven to help patients with neurologic disorders like Parkinson's Disease (Part two) and Autism (ASD autism spectum disorder). Glutathione has the abilty to reduce inflamation and ameliorate symptoms that cause several intestinal problems.

Glutathione Therapy for Parkinson’s, Dr. Perlmutter:
Part One: http://www.youtube.com/watch?v=wxno30sQkyU
Part Two: http://www.youtube.com/watch?v=k9sVN7OIKMg&feature=related
Glutathione for IBS explained by Dr. Hayman



References:
Gaby, AR. Nutritional Medicine. Fritz Perlberg Publishing, 2011
Glutathione, Reduced (GSH). Alt Med Rev, 6(6) 2001: 601-607
Schulz JB, Lindenau J, Seyfried J, Dichgans J. Glutathione, oxidative stress and neurodegeneration. Eur J Biochem 2000; 267:4904-4911.
Sechi G, Deledda MG, Bua G, et al. Reduced intravenous glutathione in the treatment of early Parkinson’s disease. Prog Neuropsychopharmacol Biol Psychiatry 1996; 20:1159-1170.
Venkateshappa C, Harrish G, Mythri RB, et al. Increased oxidative damage and decreased antioxidant function in aging human substantia nigra compared to striatum: Implications for Parkinson’s disease. Neurochem Res, 2011.

Myers Cocktail

Vitamin and Hydration Therapy

With so much going on in life – Taking care of the kids, working, traveling and taking on side projects – It’s time to recover and take care of YOU!
If you feel tired, stressed out or like you can’t turn the corner on that lingering cold, Vitamin and Hydration Therapy is for you.

Vitamin and Hydration Therapy is a highly customizable IV treatment that gives your body what it needs. We will consult with you and perfect the treatment to make sure your body has all the nutrition and hydration it needs to fire on all cylinders.

Many have turned to Vitamin and Hydration Therapy as a means to avoid the pharmacy or take Antibiotics which can wreak havoc on your gut flora. With this IV treatment, you have the peace of mind that everything is being 100% absorbed into the bloodstream. This quick, 30-minute procedure will leave you feeling refreshed and energetic.

Here is why this is the best combination

PEPTIDE THERAPY

Let's address the problem, not only the symptoms

SERMORELIN ACETATE
BENEFITS MAY INCLUDE
Increase in lean body mass
Promotes lipolysis
Increased energy
Increased strength
Accelerated wound healing Improved cardiovascular and immune function
Improves sleep quality
Improved bone density Improved skin quality and higher collagen density
Increased IGF-1

BRIEF OVERVIEW
Sermorelin (brand names Geref), is a peptide analogue of growth hormone-releasing hormone (GHRH) which is used as a diagnostic agent to assess growth hormone (GH) secretion for the purpose of diagnosing growth hormone deficiency. It is a 29-amino acid polypeptide representing the 1–29 fragment from endogenous human GHRH, thought to be the shortest fully functional fragment of GHRH.
COMMON FORMULAS & PROTOCOLS
9mg Sermorelin Freeze Dried Vial - 300mcg nightly SQ 15mg Sermorelin Freeze Dried Vial - 500mcg nightly SQ
CLINICAL REFERENCES
1 Prakash A, Goa KL (August 1999). "Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency". BioDrugs. 12 (2): 139–57. doi:10.2165/00063030-199912020-00007. PMID 18031173.
2 Pharmacology (Rang, Dale, Ritter & Moore, ISBN 0-443-07145-4, 5th ed., Churchill Livingstone 2003).
Additional references available. Contact us for more info.

GHRP2

BENEFITS MAY INCLUDE
Increased endurance
Improves recovery
Accelerated wound healing Improved cardiovascular health Increased energy
Improves sleep quality
Promotes lipolysis
Aides in the improvement of vision Improves bone density via increased calcium retention and bone mineralization Promotes gluconeogenesis in the liver
BRIEF OVERVIEW
GHRP2 substantially stimulates the pituitary gland’s increased natural production of the body’s own endogenous human growth hormone (HGH). GHRP2 has shown on its own to robustly increase IGF-1 levels, and even greater results occurred when used with Growth Hormone Releasing Hormone (GHRH) to which also stimulates the pituitary gland to produce increased natural secretion of human growth hormone. Improves hypothalamus function.
COMMON FORMULAS & PROTOCOLS
Sermorelin/GHRP2 (9/15mg) Lyophilized Vial - 300/500mcg nightly SQ for 30 days Sermorelin/GHRP2/GHRP6 (9/9/9mg) Lyophilized Vial - 300/300/300mcg nightly SQ for 30 days Sermorelin/GHRP2/GHRP6 (300/300/300mcg) Sublingual Troche - One troche daily for 30 days GHRP2/GHRP6 (300/300mcg) Sublingual Troche - One troche daily for 30 days
CLINICAL REFERENCES
1. Endocrinology. 2000;141:4325–4328. [PubMed] The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Wren AM, Small CJ, Ward HL, Murphy KG, Dakin CL, Taheri S, Kennedy AR, Roberts GH, Morgan DC, Ghatei MA, Bloom SR.
2. Science. 1996 Aug 16;273(5277):974-7. A receptor in pituitary and hypothalamus that functions in growth hormone release. Howard A.D., et al.
Additional references available. Contact us for more info.

GHRP-6
BENEFITS MAY INCLUDE
Increased anti-inflammatory response Increased stamina
Increased endurance
Muscle gain
Promotes lipolysis
Improves sleep quality
Immune system support
Stronger bones and healthier skin Increased energy
BRIEF OVERVIEW
GHRP-6 (Growth hormone-releasing peptide 6) also known as growth hormone-releasing hexapeptide, is one of several synthetic met-enkephalin analogues that include unnatural D-amino acids, were developed for their growth hormone-releasing activity and are called growth hormone secretagogues. They lack opioid activity but are potent stimulators of growth hormone (GH) release. These secretagogues are distinct from growth hormone releasing hormone (GHRH) in that they share no sequence relation and derive their function through activation of a completely different receptor.
COMMON FORMULAS & PROTOCOLS
Sermorelin/GHRP2/GHRP6 (9/9/9mg) Lyophilized Vial - 300/300/300mcg nightly SQ for 30 days GHRP2/GHRP6 (300/300mcg) Sublingual Troche - One troche daily for 30 days Sermorelin/GHRP2/GHRP6 (300/300/300mcg) Sublingual Troche - One troche daily for 30 days
CLINICAL REFERENCES
1. Science. 1996 Aug 16;273(5277):974-7. A receptor in pituitary and hypothalamus that functions in growth hormone release. Howard A.D., et al.
2. J Pediatr Endocrinol. 1993 Jul-Dec;6(3-4):283-9. Regulation of growth hormone secretion by the growth hormone releasing hexapeptide (GHRP-6). Micic D1, Mallo F, Peino R, Cordido F, Leal-Cerro A, Garcia-Mayor RV, Casanueva FF.
Additional references available. Contact us for more info.

CJC-1295
BENEFITS MAY INCLUDE
Increased protein synthesis Promotes lipolysis Improves sleep quality Increased bone density Accelerated injury recovery Improved immune system Increased protein synthesis Increased energy Increased IGF-1
Increase in lean body mass
BRIEF OVERVIEW
CJC 1295 is 30 amino acid peptide hormone that has shown promising and amazing results as a Growth Hormone Releasing Hormone (GHRH) analog. Research supports that CJC 1295 stimulates HGH secretion and can provide a steady increase of HGH with minimal effect on cortisol and prolactin levels. This means increased protein synthesis thus promoting growth and fat loss simultaneously.
COMMON FORMULAS & PROTOCOLS
CJC-1295 (10mg) Lyophilized Vial - 300 nightly SQ for 30 days
CJC-1295 / Ipamorelin (4/4mg) Lyophilized Vial - 200/200mcg daily SQ 5 days on, 2 days off
CLINICAL REFERENCES
1. Teichman, Sam L.; Neale, Ann; Lawrence, Betty; Gagnon, Catherine; Castaigne, Jean-Paul; Frohman, Lawrence A. (2006). "Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults". The Journal of Clinical Endocrinology & Metabolism. 91 (3): 799–805. doi:10.1210/jc.2005-1536. ISSN 0021-972X. PMID 16352683.
2. Ionescu, Madalina; Frohman, Lawrence A. (2006). "Pulsatile Secretion of Growth Hormone (GH) Persists during Continuous Stimulation by CJC-1295, a Long-Acting GH-Releasing Hormone Analog". The Journal of Clinical Endocrinology & Metabolism. 91 (12): 4792–4797. doi:10.1210/jc.2006-1702. ISSN 0021-972X.
Additional references available. Contact us for more info.

IPAMORELIN
BENEFITS MAY INCLUDE
Promotes lipolysis
Increased collagen production Increase in lean body mass Improves sleep quality
Increased energy
Increased endurance
Improved cellular repair
Increased IGF-1
Counteracts glucocorticoid catabolic effects
Less appetite stimulation
Less release of cortisol, prolactin and aldosterone
BRIEF OVERVIEW
Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) and a ghrelin mimetic with growth hormone (GH) releasing activity. Ipamorelin mimics ghrelin and binds to the ghrelin receptor (or GH secretagogue receptor, GHSR) in the brain, thereby selectively stimulating the release of GH from the pituitary gland. This results in increased plasma GH levels, which would affect many biological processes. Besides its presence in the brain, GHSR can also be found in the gastrointestinal tract, heart, lung, liver, kidney, pancreas, adipose tissue and immune cells. Unlike other GH releasing peptides, Ipamorelin only stimulates GH release in a manner very similar to that of growth hormone releasing hormone.
COMMON FORMULAS & PROTOCOLS
Ipamorelin (9mg) Lyophilized Vial - 300mcg daily SQ 5 days on 2 days off
Ipamorelin (300mcg) Sublingual Troche - One troche daily for 30 days
CJC-1295 / Ipamorelin (4/4mg) Lyophilized Vial - 200/200mcg daily SQ 5 days on, 2 days off
CLINICAL REFERENCES
1. Gobburu, Jogarao V. S.; Agersø, Henrik; Jusko, William J.; Ynddal, Lars (1999).Pharmacokinetic Modeling of Ipamorelin, a Growth Hormone Releasing Peptide, in Human Volunteers". Pharmaceutical Research. 16 (9): 1412–1416. doi:10.1023/A: 1018955126402. ISSN 0724-8741.
2. Raun, K; Hansen, B.; Johansen, N.; Thogersen, H; Madsen, K; Ankersen, M; Andersen, P. (1998). "Ipamorelin, the first selective growth hormone secretagogue". European Journal of Endocrinology. 139 (5): 552–561. doi:10.1530/eje.0.1390552.
ISSN 0804-4643.
Additional references available. Contact us for more info.

BPC-157 PEPTIDE THERAPY
BENEFITS MAY INCLUDE
Supports cognitive performance Supports joint health
Protects against drug-induced damage Restores the serotogenic transport system
Protects dopaminergic system Enhances the GABAergic system Reverse opioid tolerance Accelerated wound healing Ligament healing (knee, rotary) Benefits for ulcers in the stomach Benefits for intestinal damage
May help irritable bowel disease May help with urinary incontinence Promotes lipolysis
BRIEF OVERVIEW
BPC 157, composed of 15 amino acids, is a partial sequence of body protection compound (BPC) that is discovered in and isolated from human gastric juice. Experimentally it has been demonstrated to accelerate the healing of many different wounds, including tendons, muscles, nervous system and superior healing of damaged ligaments. Those who suffer from discomfort due to muscle sprains, tears and damage may benefit from treatment with this peptide. It can also help aid skin burns to heal at a faster rate and increase blood flow to damaged tissues.
COMMON FORMULAS & PROTOCOLS
BPC-157 (10mg) Lyophilized Vial - 300 nightly SQ for 30 days
BPC-157 (500mcg) Sublingual Troche - One troche daily for 30 days BPC-157 (500mcg) Rectal Suppository - One suppository daily for 30 days BPC-157 (1mg/g) Topical Cream - Apply 1/4g - 1 g daily for 30 days

CLINICAL REFERENCES
1. Cerovecki, Tomislav; Bojanic, Ivan; Brcic, Luka; Radic, Bozo; Vukoja, Ivan; Seiwerth, Sven; Sikiric, Predrag (September 2010). "Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat". Journal of Orthopaedic Research. 28 (9): 1155– 1161. doi:10.1002/jor.21107. ISSN 1554-527X. PMID 20225319.
2. "Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response". PMID 17186181.
Additional references available. Contact us for more info.

ADDITIONAL REFERENCES PEPTIDE THERAPY SERMORELIN
1. Vitiello MV, Schwartz RS, Moe KE, Mazzoni G, Merriam GR. 2001 Treating age-related changes in somatotrophic hormones, sleep, and cognition. In Health, age, hormones, sleep, and cognition Dialogues in Clinical Neuroscience – Vol 3. No. 3.
2. Esposito P, Barbero L, Caccia P, Caliceti P, D'Antonio M, Piquet G, Veronese FM: PEGylation of growth hormone-releasing hormone (GRF) analogues. Adv Drug Deliv Rev. 2003 Sep 26;55(10):1279-91. [PubMed:14499707]
3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
4. Toogood AA, Beardwell CG, Shalet SM. 1994 The severity of growth hormone deficiency in adults with pituitary disease is related to the
degree of hypopituitarism. Clin Endocrinol (Oxf). 41:511–516.
5. Merriam GR, Schwartz RS, Vitiello MV. Growth hormone-releasing hormone and growth hormone secretagogues in normal aging.
Endocrine. 2003 Oct; 22(1):41-8.
6. Walker, R.F., 2006. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging, 1(4):
p. 307-8.
7. Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing
hormone-(1-29)-NH2 in age-advancing men and women. J Clin Endocrinol Metab. 1997 May; 82(5):1472-9.
GHRP-2
1. J Clin Endocrinol Metab. 1998;83(4):1168–1172. [PubMed] Pharmacokinetics and pharmacodynamics of growth hormone-releasing peptide-2: a phase I study in children. Pihoker C, Kearns GL, French D, Bowers CY.
2. Science. 1996 Aug 16;273(5277):974-7. A receptor in pituitary and hypothalamus that functions in growth hormone release. Howard A.D., et al.
3. Eur J Endocrinol. 2001;145:669–673. [PubMed] Weight gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa. Otto B, Cuntz U, Fruehauf E, Warwarta R, Folwaczny C, Riepl RL, Heiman ML, Lehnart P, Fichter M, Tschop M.
4. Diabetes. 2001;50:707–709. [PubMed] Circulating ghrelin levels are decreased in human obesity. Tschop M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E, Heiman ML.
5. Topic Endocrinol Suppl. 2001;2:39–40. Ghrelin provides the calories that growth hormone requires for growth and repair. Heiman ML, Tschop M.
GHRP-6
1. J Pediatr Endocrinol. 1993 Jul-Dec;6(3-4):283-9. Regulation of growth hormone secretion by the growth hormone releasing hexapeptide (GHRP-6). Micic D1, Mallo F, Peino R, Cordido F, Leal-Cerro A, Garcia-Mayor RV, Casanueva FF.
2. Endocr Regul. 2012 Apr;46(2):73-81. Protective effect of GHRP-6 and estrogen supplementation against some cardiometabolic risk factors in ovariectomized rats. Elbassuoni E1, Ragy M, Aziz N.
3. Int J Obes Relat Metab Disord. 1999 Mar;23(3):260-71. Growth hormone in obesity. Scacchi M1, Pincelli AI, Cavagnini F.
4. Mol Endocrinol. 1996 Jan;10(1):57-61. Identification of a new G-protein-linked receptor for growth hormone secretagogues. Pong SS1,
Chaung LY, Dean DC, Nargund RP, Patchett AA, Smith RG.
PEPTIDE THERAPY ADDITIONAL REFERENCES CJC-1295
1. Jetté, Lucie; Léger, Roger; Thibaudeau, Karen; Benquet, Corinne; Robitaille, Martin; Pellerin, Isabelle; Paradis, Véronique; van Wyk, Pieter; Pham, Khan; Bridon, Dominique P. (2005). "Human Growth Hormone-Releasing Factor (hGRF)1–29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog" (PDF). Endocrinology. 146 (7): 3052–3058. doi:10.1210/en.2004-1286. ISSN 0013-7227. PMID 15817669.
2. Teichman, Sam L.; Neale, Ann; Lawrence, Betty; Gagnon, Catherine; Castaigne, Jean-Paul; Frohman, Lawrence A. (2006). "Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults". The Journal of Clinical Endocrinology & Metabolism. 91 (3): 799–805. doi:10.1210/jc.2005-1536.
ISSN 0021-972X. PMID 16352683.
3. Ionescu, Madalina; Frohman, Lawrence A. (2006). "Pulsatile Secretion of Growth Hormone (GH) Persists during Continuous Stimulation by CJC-1295, a Long-Acting GH-Releasing Hormone Analog". The Journal of Clinical Endocrinology & Metabolism. 91 (12): 4792– 4797. doi:10.1210/jc.2006-1702. ISSN 0021-972X.
4. Henninge, John; Pepaj, Milaim; Hullstein, Ingunn; Hemmersbach, Peter (2010). "Identification of CJC-1295, a growth-hormone- releasing peptide, in an unknown pharmaceutical preparation". Drug Testing and Analysis. 2 (11–12): 647–650. doi:10.1002/dta.233. ISSN 1942-7603.
5. Thorner, Michael O. (2008). "The Discovery of Growth Hormone-Releasing Hormone1: An Update". Journal of Neuroendocrinology. 20 (6): 653–654. doi:10.1111/j.1365-2826.2008.01740.x. ISSN 0953-8194.
IPAMORELIN
1 Gobburu, Jogarao V. S.; Agersø, Henrik; Jusko, William J.; Ynddal, Lars (1999). "Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin, a Growth Hormone Releasing Peptide, in Human Volunteers". Pharmaceutical Research. 16 (9): 1412–1416. doi:10.1023/A: 1018955126402. ISSN 0724-8741.
2 Moulin, Aline; Ryan, Joanne; Martinez, Jean; Fehrentz, Jean-Alain (2007). "Recent Developments in Ghrelin Receptor Ligands". ChemMedChem. 2 (9): 1242–1259. doi:10.1002/cmdc.200700015. ISSN 1860-7179. PMID 17520591.
3 Raun, K; Hansen, B.; Johansen, N.; Thogersen, H; Madsen, K; Ankersen, M; Andersen, P. (1998). "Ipamorelin, the first selective growth hormone secretagogue". European Journal of Endocrinology. 139 (5): 552–561. doi:10.1530/eje.0.1390552. ISSN 0804-4643.
4 Isidro, Maria; Cordido, Fernando (2006). "Growth Hormone Secretagogues". Combinatorial Chemistry & High Throughput Screening. 9 (3): 175–180. doi:10.2174/138620706776055458. ISSN 1386-2073.
5 Estrada, R. Cañete; Jiménez-Reina, L.; de la Torre, M.J.; Bernal, J. (2002). "Chronic In Vivo Ipamorelin Treatment Stimulates Body Weight Gain and Growth Hormone (GH) Release In Vitro in Young Female Rats". 6 (1): 37–46. ISSN 1136-4890.
BPC-157
1. Sikiric P, et al. Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Curr Neuropharmacol. (2016) 2. Klicek R, et al. Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon-anastomosis and counteracts
cuprizone brain injuries and motor disability. J Physiol Pharmacol. (2013)
3. Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and
cell migration. J Appl Physiol (1985). (2011)
4. Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates
tendocytes growth. J Orthop Res. (2003)
5. Jenkins TA, et al. Influence of Tryptophan and Serotonin on Mood and Cognition with a Possible Role of the Gut-Brain Axis. Nutrients.(2016)